Dechra Pharmaceuticals PLC Stock Forecast for 2023 - 2025 - 2030
Updated on 04/20/2024
Dechra Pharmaceuticals PLC Stock Forecast and Price Target
If the average price target of £20.98 set by four distinguished experts for Dechra Pharmaceuticals PLC over the past few weeks is reached this year, there would be a potential downside of approximately -45.73% from the last closing price in January, 2024. This potential increase is based on a high estimate of £23.50 and a low estimate of £18.67. If you're interested in DPH stock, looking at its competitors might also be a good idea.
-45.73% Downside
Dechra Pharmaceuticals PLC Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Dechra Pharmaceuticals PLC's Price has decreased from £30.64 to £0.00 – a 100.00% drop! Next year, analysts are expecting Fair Value to reach £41.96 – an increase of 100.00%. Over the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MRK Stock Forecast | Merck | Outperform |
2
|
$125.78 | Buy/Sell | $130.51 | 10.91% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$146.50 | Buy/Sell | $220.47 | 51.19% |
| IDXX Stock Forecast | IDEXX Laboratories | Outperform |
14
|
$476.35 | Buy/Sell | $583.92 | 25.96% |
| ELAN Stock Forecast | Elanco Animal Health | Outperform |
13
|
$12.95 | Buy/Sell | $14.90 | 39.00% |
| VIRP Stock Forecast | Virbac | Outperform |
18
|
376.00€ | Buy/Sell | 348.34€ | -1.86% |
Dechra Pharmaceuticals PLC Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Dechra Pharmaceuticals PLC's Revenue has grown from £515.10M to £761.50M – a 47.84% increase. Next year, analysts are expecting Revenue to reach £824.81M – an increase of 8.31%. Over the next seven years, the forecast is for Revenue to grow by 18.67%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VETO Stock Forecast | Vetoquinol | Outperform |
18
|
96.10€ | Buy/Sell | 106.50€ | 14.46% |
| PAHC Stock Forecast | Phibro Animal Health | Underperform |
18
|
$13.30 | Buy/Sell | $12.50 | -21.05% |
| APDN Stock Forecast | Applied DNA Sciences | Outperform |
10
|
$0.34 | Buy/Sell | $2.50 | 561.76% |
.jpg)
Dechra Pharmaceuticals PLC Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Dechra Pharmaceuticals PLC has seen a decline in its Dividend per Share, from £0.34 to £0.13 – a 61.76% decrease. For next year, analysts predict Dividend per Share of £0.48, which would mean an increase of 269.23%. Over the next seven years, experts predict that Dechra Pharmaceuticals PLC's Dividend per Share will grow at a rate of 346.24%.
Dechra Pharmaceuticals PLC EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Dechra Pharmaceuticals PLC's EBITDA has fallen from £81.20M to £62.20M – a 23.40% decrease. In the next year, analysts believe that EBITDA will reach £228.33M – an increase of 267.09%. For the next seven years, the forecast is for EBITDA to grow by 304.11%.
Dechra Pharmaceuticals PLC EBIT Forecast for 2023 - 2025 - 2030
Dechra Pharmaceuticals PLC's EBIT has decreased In the last three years, from £58.70M to £17.10M – a 70.87% drop. In the next year, analysts believe that EBIT will reach £202.10M – an increase of 1081.87%. For the next seven years, experts predict that Dechra Pharmaceuticals PLC's EBIT will grow at a rate of 1245.47%.
Dechra Pharmaceuticals PLC EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Dechra Pharmaceuticals PLC's EPS has decreased from £0.92 to £0.00 – a 100.00% drop! Next year, analysts are expecting EPS to reach £1.26 – an increase of 100.00%. Over the next seven years, the forecast is for EPS to grow by 100.00%.
Site Navigation
.jpg)